Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein.
Identifieur interne : 000F47 ( PubMed/Checkpoint ); précédent : 000F46; suivant : 000F48Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein.
Auteurs : Nicolas Escriou [France] ; Benoît Callendret [France] ; Valérie Lorin [France] ; Chantal Combredet [France] ; Philippe Marianneau [France] ; Michèle Février [France] ; Frédéric Tangy [France]Source :
- Virology [ 1096-0341 ] ; 2014.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (immunologie), Anticorps neutralisants (immunologie), Glycoprotéine de spicule des coronavirus (administration et posologie), Glycoprotéine de spicule des coronavirus (génétique), Glycoprotéine de spicule des coronavirus (immunologie), Humains, Lymphocytes auxiliaires Th1 (immunologie), Mâle, Souris, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (virologie), Vaccin contre la rougeole (génétique), Vaccin contre la rougeole (immunologie), Vaccins antiviraux (administration et posologie), Vaccins antiviraux (génétique), Vaccins antiviraux (immunologie), Vecteurs génétiques (génétique), Vecteurs génétiques (immunologie), Virus de la rougeole (génétique), Virus de la rougeole (immunologie), Virus du SRAS (génétique), Virus du SRAS (immunologie), Virus du SRAS (physiologie).
- MESH :
- administration et posologie : Glycoprotéine de spicule des coronavirus, Vaccins antiviraux.
- génétique : Glycoprotéine de spicule des coronavirus, Vaccin contre la rougeole, Vaccins antiviraux, Vecteurs génétiques, Virus de la rougeole, Virus du SRAS.
- immunologie : Anticorps antiviraux, Anticorps neutralisants, Glycoprotéine de spicule des coronavirus, Lymphocytes auxiliaires Th1, Syndrome respiratoire aigu sévère, Vaccin contre la rougeole, Vaccins antiviraux, Vecteurs génétiques, Virus de la rougeole, Virus du SRAS.
- physiologie : Virus du SRAS.
- virologie : Syndrome respiratoire aigu sévère.
- Animaux, Humains, Mâle, Souris, Syndrome respiratoire aigu sévère.
English descriptors
- KwdEn :
- Animals, Antibodies, Neutralizing (immunology), Antibodies, Viral (immunology), Genetic Vectors (genetics), Genetic Vectors (immunology), Humans, Male, Measles Vaccine (genetics), Measles Vaccine (immunology), Measles virus (genetics), Measles virus (immunology), Mice, SARS Virus (genetics), SARS Virus (immunology), SARS Virus (physiology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (virology), Spike Glycoprotein, Coronavirus (administration & dosage), Spike Glycoprotein, Coronavirus (genetics), Spike Glycoprotein, Coronavirus (immunology), Th1 Cells (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (genetics), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Spike Glycoprotein, Coronavirus, Viral Vaccines.
- chemical , genetics : Measles Vaccine, Spike Glycoprotein, Coronavirus, Viral Vaccines.
- chemical , immunology : Antibodies, Neutralizing, Antibodies, Viral, Measles Vaccine, Spike Glycoprotein, Coronavirus, Viral Vaccines.
- genetics : Genetic Vectors, Measles virus, SARS Virus.
- immunology : Genetic Vectors, Measles virus, SARS Virus, Severe Acute Respiratory Syndrome, Th1 Cells.
- physiology : SARS Virus.
- prevention & control : Severe Acute Respiratory Syndrome.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Humans, Male, Mice.
Abstract
The recent identification of a novel human coronavirus responsible of a SARS-like illness in the Middle-East a decade after the SARS pandemic, demonstrates that reemergence of a SARS-like coronavirus from an animal reservoir remains a credible threat. Because SARS is contracted by aerosolized contamination of the respiratory tract, a vaccine inducing mucosal long-term protection would be an asset to control new epidemics. To this aim, we generated live attenuated recombinant measles vaccine (MV) candidates expressing either the membrane-anchored SARS-CoV spike (S) protein or its secreted soluble ectodomain (Ssol). In mice susceptible to measles virus, recombinant MV expressing the anchored full-length S induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV. As compared to immunization with adjuvanted recombinant Ssol protein, recombinant MV induced stronger and Th1-biased responses, a hallmark of live attenuated viruses and a highly desirable feature for an antiviral vaccine.
DOI: 10.1016/j.virol.2014.01.002
PubMed: 24606680
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:24606680Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein.</title>
<author><name sortKey="Escriou, Nicolas" sort="Escriou, Nicolas" uniqKey="Escriou N" first="Nicolas" last="Escriou">Nicolas Escriou</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France. Electronic address: nicolas.escriou@pasteur.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Callendret, Benoit" sort="Callendret, Benoit" uniqKey="Callendret B" first="Benoît" last="Callendret">Benoît Callendret</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lorin, Valerie" sort="Lorin, Valerie" uniqKey="Lorin V" first="Valérie" last="Lorin">Valérie Lorin</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Combredet, Chantal" sort="Combredet, Chantal" uniqKey="Combredet C" first="Chantal" last="Combredet">Chantal Combredet</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marianneau, Philippe" sort="Marianneau, Philippe" uniqKey="Marianneau P" first="Philippe" last="Marianneau">Philippe Marianneau</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut Pasteur, Unité de Biologie des Infections Virales Emergentes, Département de Virologie, F-69007 Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Pasteur, Unité de Biologie des Infections Virales Emergentes, Département de Virologie, F-69007 Lyon</wicri:regionArea>
<placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fevrier, Michele" sort="Fevrier, Michele" uniqKey="Fevrier M" first="Michèle" last="Février">Michèle Février</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tangy, Frederic" sort="Tangy, Frederic" uniqKey="Tangy F" first="Frédéric" last="Tangy">Frédéric Tangy</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France. Electronic address: frederic.tangy@pasteur.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24606680</idno>
<idno type="pmid">24606680</idno>
<idno type="doi">10.1016/j.virol.2014.01.002</idno>
<idno type="wicri:Area/PubMed/Corpus">001032</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001032</idno>
<idno type="wicri:Area/PubMed/Curation">001032</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001032</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000F47</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F47</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein.</title>
<author><name sortKey="Escriou, Nicolas" sort="Escriou, Nicolas" uniqKey="Escriou N" first="Nicolas" last="Escriou">Nicolas Escriou</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France. Electronic address: nicolas.escriou@pasteur.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Callendret, Benoit" sort="Callendret, Benoit" uniqKey="Callendret B" first="Benoît" last="Callendret">Benoît Callendret</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lorin, Valerie" sort="Lorin, Valerie" uniqKey="Lorin V" first="Valérie" last="Lorin">Valérie Lorin</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Combredet, Chantal" sort="Combredet, Chantal" uniqKey="Combredet C" first="Chantal" last="Combredet">Chantal Combredet</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marianneau, Philippe" sort="Marianneau, Philippe" uniqKey="Marianneau P" first="Philippe" last="Marianneau">Philippe Marianneau</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut Pasteur, Unité de Biologie des Infections Virales Emergentes, Département de Virologie, F-69007 Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Pasteur, Unité de Biologie des Infections Virales Emergentes, Département de Virologie, F-69007 Lyon</wicri:regionArea>
<placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region>
<region type="old region" nuts="2">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fevrier, Michele" sort="Fevrier, Michele" uniqKey="Fevrier M" first="Michèle" last="Février">Michèle Février</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tangy, Frederic" sort="Tangy, Frederic" uniqKey="Tangy F" first="Frédéric" last="Tangy">Frédéric Tangy</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France. Electronic address: frederic.tangy@pasteur.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Virology</title>
<idno type="eISSN">1096-0341</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Neutralizing (immunology)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Genetic Vectors (genetics)</term>
<term>Genetic Vectors (immunology)</term>
<term>Humans</term>
<term>Male</term>
<term>Measles Vaccine (genetics)</term>
<term>Measles Vaccine (immunology)</term>
<term>Measles virus (genetics)</term>
<term>Measles virus (immunology)</term>
<term>Mice</term>
<term>SARS Virus (genetics)</term>
<term>SARS Virus (immunology)</term>
<term>SARS Virus (physiology)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
<term>Severe Acute Respiratory Syndrome (prevention & control)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
<term>Spike Glycoprotein, Coronavirus (administration & dosage)</term>
<term>Spike Glycoprotein, Coronavirus (genetics)</term>
<term>Spike Glycoprotein, Coronavirus (immunology)</term>
<term>Th1 Cells (immunology)</term>
<term>Viral Vaccines (administration & dosage)</term>
<term>Viral Vaccines (genetics)</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Anticorps neutralisants (immunologie)</term>
<term>Glycoprotéine de spicule des coronavirus (administration et posologie)</term>
<term>Glycoprotéine de spicule des coronavirus (génétique)</term>
<term>Glycoprotéine de spicule des coronavirus (immunologie)</term>
<term>Humains</term>
<term>Lymphocytes auxiliaires Th1 (immunologie)</term>
<term>Mâle</term>
<term>Souris</term>
<term>Syndrome respiratoire aigu sévère ()</term>
<term>Syndrome respiratoire aigu sévère (immunologie)</term>
<term>Syndrome respiratoire aigu sévère (virologie)</term>
<term>Vaccin contre la rougeole (génétique)</term>
<term>Vaccin contre la rougeole (immunologie)</term>
<term>Vaccins antiviraux (administration et posologie)</term>
<term>Vaccins antiviraux (génétique)</term>
<term>Vaccins antiviraux (immunologie)</term>
<term>Vecteurs génétiques (génétique)</term>
<term>Vecteurs génétiques (immunologie)</term>
<term>Virus de la rougeole (génétique)</term>
<term>Virus de la rougeole (immunologie)</term>
<term>Virus du SRAS (génétique)</term>
<term>Virus du SRAS (immunologie)</term>
<term>Virus du SRAS (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Measles Vaccine</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
<term>Measles Vaccine</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term>
<term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Genetic Vectors</term>
<term>Measles virus</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term>
<term>Vaccin contre la rougeole</term>
<term>Vaccins antiviraux</term>
<term>Vecteurs génétiques</term>
<term>Virus de la rougeole</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps neutralisants</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Lymphocytes auxiliaires Th1</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Vaccin contre la rougeole</term>
<term>Vaccins antiviraux</term>
<term>Vecteurs génétiques</term>
<term>Virus de la rougeole</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Genetic Vectors</term>
<term>Measles virus</term>
<term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
<term>Th1 Cells</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
<term>Male</term>
<term>Mice</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
<term>Mâle</term>
<term>Souris</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The recent identification of a novel human coronavirus responsible of a SARS-like illness in the Middle-East a decade after the SARS pandemic, demonstrates that reemergence of a SARS-like coronavirus from an animal reservoir remains a credible threat. Because SARS is contracted by aerosolized contamination of the respiratory tract, a vaccine inducing mucosal long-term protection would be an asset to control new epidemics. To this aim, we generated live attenuated recombinant measles vaccine (MV) candidates expressing either the membrane-anchored SARS-CoV spike (S) protein or its secreted soluble ectodomain (Ssol). In mice susceptible to measles virus, recombinant MV expressing the anchored full-length S induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV. As compared to immunization with adjuvanted recombinant Ssol protein, recombinant MV induced stronger and Th1-biased responses, a hallmark of live attenuated viruses and a highly desirable feature for an antiviral vaccine. </div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24606680</PMID>
<DateCompleted><Year>2014</Year>
<Month>05</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0341</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>452-453</Volume>
<PubDate><Year>2014</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Virology</Title>
<ISOAbbreviation>Virology</ISOAbbreviation>
</Journal>
<ArticleTitle>Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein.</ArticleTitle>
<Pagination><MedlinePgn>32-41</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virol.2014.01.002</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0042-6822(14)00005-1</ELocationID>
<Abstract><AbstractText>The recent identification of a novel human coronavirus responsible of a SARS-like illness in the Middle-East a decade after the SARS pandemic, demonstrates that reemergence of a SARS-like coronavirus from an animal reservoir remains a credible threat. Because SARS is contracted by aerosolized contamination of the respiratory tract, a vaccine inducing mucosal long-term protection would be an asset to control new epidemics. To this aim, we generated live attenuated recombinant measles vaccine (MV) candidates expressing either the membrane-anchored SARS-CoV spike (S) protein or its secreted soluble ectodomain (Ssol). In mice susceptible to measles virus, recombinant MV expressing the anchored full-length S induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV. As compared to immunization with adjuvanted recombinant Ssol protein, recombinant MV induced stronger and Th1-biased responses, a hallmark of live attenuated viruses and a highly desirable feature for an antiviral vaccine. </AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Escriou</LastName>
<ForeName>Nicolas</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France. Electronic address: nicolas.escriou@pasteur.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Callendret</LastName>
<ForeName>Benoît</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lorin</LastName>
<ForeName>Valérie</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France; Univ. Paris Diderot, Sorbonne, Paris Cité, EA 302, F-75015 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Combredet</LastName>
<ForeName>Chantal</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Marianneau</LastName>
<ForeName>Philippe</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Institut Pasteur, Unité de Biologie des Infections Virales Emergentes, Département de Virologie, F-69007 Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Février</LastName>
<ForeName>Michèle</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tangy</LastName>
<ForeName>Frédéric</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Institut Pasteur, Unité de Génomique Virale et Vaccination, Département de Virologie, F-75015 Paris, France; CNRS, UMR 3569, F-75015 Paris, France. Electronic address: frederic.tangy@pasteur.fr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>01</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Virology</MedlineTA>
<NlmUniqueID>0110674</NlmUniqueID>
<ISSNLinking>0042-6822</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008458">Measles Vaccine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008458" MajorTopicYN="N">Measles Vaccine</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008459" MajorTopicYN="N">Measles virus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018417" MajorTopicYN="N">Th1 Cells</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus</Keyword>
<Keyword MajorTopicYN="N">Measles vaccine</Keyword>
<Keyword MajorTopicYN="N">Severe acute respiratory syndrome</Keyword>
<Keyword MajorTopicYN="N">Spike glycoprotein</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year>
<Month>10</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2013</Year>
<Month>11</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>01</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>3</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>3</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>5</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24606680</ArticleId>
<ArticleId IdType="pii">S0042-6822(14)00005-1</ArticleId>
<ArticleId IdType="doi">10.1016/j.virol.2014.01.002</ArticleId>
<ArticleId IdType="pmc">PMC7111909</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Vaccine. 2006 Apr 24;24(17):3624-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16497416</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2005 Mar 30;334(1):74-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15749124</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2011 Jul;85(14):7095-107</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21543501</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2004 Sep 15;190(6):1119-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15319862</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2006 Jun;80(12):5757-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16731915</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Pediatr Infect Dis J. 2000 Dec;19(12):1211-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11144388</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Vaccine Immunol. 2011 Mar;18(3):355-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21228137</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2005 Sep 30;340(2):174-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16043204</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS One. 2012;7(4):e35421</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22536382</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 2008 Apr;133(1):45-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17416434</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Oct;78(19):10328-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15367599</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2005 Jan 15;191(2):207-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15609230</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2007 Jul 5;363(2):288-302</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17331558</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Naunyn Schmiedebergs Arch Pharmacol. 2012 Dec;385(12):1211-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22983013</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2139-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15220038</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2009 May 25;388(1):191-203</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19345390</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS One. 2012;7(11):e50397</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23226275</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 1997 Jan 20;227(2):314-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9018130</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2005 Aug;11(8):1312-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16110580</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Clin Microbiol. 2004 May;42(5):2043-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15131168</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2003 Nov;77(21):11546-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14557640</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 2008 Apr;133(1):20-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17499378</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2005 Mar;79(5):2678-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15708987</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15616839</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Drugs Today (Barc). 2008 Jan;44(1):63-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18301805</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 2004 Jan 30;279(5):3197-201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14670965</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Antimicrob Chemother. 2005 Nov;56(5):919-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16183666</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2005 May 2;23(24):3202-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15837221</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2013 Jun;87(12):6551-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23576515</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2011 Dec;85(23):12201-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21937658</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 Dec 4;58(47):1321-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19959985</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12111-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22773820</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15210961</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Viral Immunol. 2005;18(2):317-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16035943</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>New Microbiol. 2012 Jan;35(1):1-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22378548</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2006 Mar 1;193(5):685-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16453264</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Expert Rev Vaccines. 2009 Jul;8(7):887-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19538115</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16081529</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):797-801</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15642942</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2013 Aug 12;31(36):3718-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23742993</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Med. 2006 Jun;3(6):e177</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16683867</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2012 Jul 15;206(2):212-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22551814</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2003 Jun 2;21(19-20):2580-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12744894</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1998 Sep;72(9):7420-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9696838</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2010 Dec;84(24):12658-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20926566</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2011 Jun 1;203(11):1574-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21592986</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Med. 2006 Dec;3(12):e525</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17194199</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2011 Jan;85(1):217-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20980507</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2006 Aug;80(16):7918-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16873249</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2001 Oct 1;184(7):817-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11528592</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Pathog. 2010 Apr 08;6(4):e1000849</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20386712</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2004 Mar 12;22(9-10):1214-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15003650</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Negl Trop Dis. 2007 Dec 12;1(3):e96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18160988</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>mBio. 2013 Aug 20;4(4):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23963179</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2005 Apr 10;334(2):160-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15780866</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2002 Jun 21;20(21-22):2790-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12034106</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2005 Sep;79(18):11892-900</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16140765</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Jan;78(1):146-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14671096</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol Methods. 2005 Sep;128(1-2):21-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15885812</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2008 Aug;82(15):7721-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18463152</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1993 Aug;67(8):4822-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8392616</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2003 Jul 28;21(24):3398-405</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12850348</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>BMJ. 2011 Jun 15;342:d3724</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21677008</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2008 Apr 16;26(17):2164-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18346823</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2430-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15695582</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Oct;78(20):11416-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15452265</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2005 Oct 28;310(5748):676-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16195424</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2005 Oct 25;341(2):215-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16099010</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<region><li>Auvergne-Rhône-Alpes</li>
<li>Rhône-Alpes</li>
<li>Île-de-France</li>
</region>
<settlement><li>Lyon</li>
<li>Paris</li>
</settlement>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Escriou, Nicolas" sort="Escriou, Nicolas" uniqKey="Escriou N" first="Nicolas" last="Escriou">Nicolas Escriou</name>
</region>
<name sortKey="Callendret, Benoit" sort="Callendret, Benoit" uniqKey="Callendret B" first="Benoît" last="Callendret">Benoît Callendret</name>
<name sortKey="Combredet, Chantal" sort="Combredet, Chantal" uniqKey="Combredet C" first="Chantal" last="Combredet">Chantal Combredet</name>
<name sortKey="Fevrier, Michele" sort="Fevrier, Michele" uniqKey="Fevrier M" first="Michèle" last="Février">Michèle Février</name>
<name sortKey="Lorin, Valerie" sort="Lorin, Valerie" uniqKey="Lorin V" first="Valérie" last="Lorin">Valérie Lorin</name>
<name sortKey="Marianneau, Philippe" sort="Marianneau, Philippe" uniqKey="Marianneau P" first="Philippe" last="Marianneau">Philippe Marianneau</name>
<name sortKey="Tangy, Frederic" sort="Tangy, Frederic" uniqKey="Tangy F" first="Frédéric" last="Tangy">Frédéric Tangy</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000F47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:24606680 |texte= Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:24606680" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |